{"title":"Exploring the unexplored: identifying knowledge gaps in novel pharmacological treatments for diabetic retinopathy","authors":"Amin Sharifan, Sobha Sivaprasad","doi":"10.1038/s41433-024-03349-x","DOIUrl":null,"url":null,"abstract":"<p>Diabetic retinopathy is a serious condition that can lead to diabetic macular oedema or vision loss. In 2020, approximately 103·12 million diabetic patients worldwide were affected by retinopathy. This number is projected to increase to 129·84 million and 160·50 million in 2030 and 2045, respectively. Regions most impacted by diabetic retinopathy are anticipated to be the Western Pacific, Middle East and North Africa, and North America and Caribbean [1].</p><p>Whilst anti-vascular endothelial growth factor treatment has improved visual outcomes for patients with diabetic retinopathy, reports indicate that some do not achieve complete resolution of diabetic macular oedema, and most require multiple injections and prolonged treatments. These limitations have spurred interest in novel agents with more effective control of diabetic retinopathy [2].</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41433-024-03349-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0
Abstract
Diabetic retinopathy is a serious condition that can lead to diabetic macular oedema or vision loss. In 2020, approximately 103·12 million diabetic patients worldwide were affected by retinopathy. This number is projected to increase to 129·84 million and 160·50 million in 2030 and 2045, respectively. Regions most impacted by diabetic retinopathy are anticipated to be the Western Pacific, Middle East and North Africa, and North America and Caribbean [1].
Whilst anti-vascular endothelial growth factor treatment has improved visual outcomes for patients with diabetic retinopathy, reports indicate that some do not achieve complete resolution of diabetic macular oedema, and most require multiple injections and prolonged treatments. These limitations have spurred interest in novel agents with more effective control of diabetic retinopathy [2].
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
